BioSpace News Archive

Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced that the Company granted a non-qualified stock option and restricted stock units to Elaine O’Hara, its newly appointed Chief Strategy Officer, as a material inducement for her entry into employment with Novavax, effective as of March 1, 2023.

DBV Technologies announces filing of 2022Annual Report on Form 10-K and 2022Universal Registration Document

Exelixis, Inc. announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival.

Santhera Pharmaceuticals announces that it has submitted a marketing authorization application to the UK Medicines and Healthcare products Regulatory Agency for vamorolone for the treatment of Duchenne muscular dystrophy.

Company Announcement – No. 2 / 2023 Zealand convenes its Annual General Meeting 2023.

argenx reported financial results for the full year 2022 and provided a fourth quarter business update.

Biophytis SA announced that it has signed a master service agreement with the pharmaceutical company Intsel Chimos, which will become its Pharmaceutical Operator/Exploitant in France for Sarconeos in the context of the early access program application, requested for the treatment of severe forms of COVID-19, if approved.

111, Inc. today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2022 ended December 31, 2022.

Sobi® and Sanofi announced that the XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa as once-weekly prophylaxis in previously treated patients under 12 years of age with severe haemophilia A met its primary endpoint.

RNA delivery and therapeutics company SiSaf Ltd announces its collaboration with the University of Leipzig, Germany, to develop Bio-Courier targeted micro interfering RNAs for the treatment of cancer, with an initial focus on pancreatic cancer.